Vanguard Group Inc. Has $514.67 Million Holdings in Guardant Health, Inc. (NASDAQ:GH)

Vanguard Group Inc. grew its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 0.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,081,377 shares of the company’s stock after acquiring an additional 28,826 shares during the period. Vanguard Group Inc. owned 9.75% of Guardant Health worth $514,667,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of GH. Two Sigma Advisers LP boosted its stake in shares of Guardant Health by 96.7% in the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock valued at $70,742,000 after buying an additional 1,138,300 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Guardant Health in the fourth quarter valued at approximately $26,673,000. Emerald Advisers LLC bought a new stake in shares of Guardant Health in the first quarter valued at approximately $22,639,000. Two Sigma Investments LP boosted its stake in shares of Guardant Health by 38.5% in the fourth quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company’s stock valued at $57,761,000 after buying an additional 525,368 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of Guardant Health by 4,838.8% in the first quarter. Principal Financial Group Inc. now owns 498,129 shares of the company’s stock valued at $21,220,000 after buying an additional 488,043 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GH shares. Raymond James Financial upped their target price on Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, July 31st. Barclays upped their price target on shares of Guardant Health from $55.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, May 1st. Scotiabank increased their price objective on Guardant Health from $57.00 to $60.00 and gave the company a “sector outperform” rating in a report on Thursday, July 31st. Mizuho increased their price objective on Guardant Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Friday, June 13th. Finally, TD Securities increased their price objective on Guardant Health from $56.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, May 1st. Sixteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Guardant Health presently has an average rating of “Buy” and an average target price of $57.50.

Guardant Health Stock Performance

NASDAQ:GH opened at $60.36 on Friday. The firm has a market cap of $7.53 billion, a price-to-earnings ratio of -18.02 and a beta of 1.43. Guardant Health, Inc. has a 52 week low of $20.14 and a 52 week high of $60.68. The firm has a 50-day moving average price of $49.00 and a two-hundred day moving average price of $45.48.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to analysts’ expectations of $211.19 million. The company’s quarterly revenue was up 31.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.84) EPS. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Musa Tariq sold 3,213 shares of Guardant Health stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $49.47, for a total value of $158,947.11. Following the completion of the transaction, the director directly owned 7,190 shares in the company, valued at approximately $355,689.30. The trade was a 30.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 3,337 shares of Guardant Health stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $47.22, for a total transaction of $157,573.14. Following the completion of the transaction, the director owned 11,150 shares of the company’s stock, valued at $526,503. This represents a 23.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 235,516 shares of company stock worth $11,848,754 in the last three months. Insiders own 6.10% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.